Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Total Liabilities (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Total Liabilities data on record, last reported at $22.1 million in Q3 2025.

  • For Q3 2025, Total Liabilities fell 41.45% year-over-year to $22.1 million; the TTM value through Sep 2025 reached $22.1 million, down 41.45%, while the annual FY2024 figure was $33.1 million, 2.06% up from the prior year.
  • Total Liabilities reached $22.1 million in Q3 2025 per RANI's latest filing, down from $26.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $201.0 million in Q2 2021 and bottomed at $2.6 million in Q4 2021.
  • Average Total Liabilities over 5 years is $39.9 million, with a median of $33.1 million recorded in 2024.
  • The widest YoY moves for Total Liabilities: up 1188.75% in 2022, down 97.17% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $2.6 million in 2021, then surged by 1188.75% to $34.0 million in 2022, then decreased by 4.56% to $32.5 million in 2023, then rose by 2.06% to $33.1 million in 2024, then crashed by 33.28% to $22.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $22.1 million in Q3 2025, $26.1 million in Q2 2025, and $29.5 million in Q1 2025.